Vanguard Group Inc. Raises Stock Position in Bausch Health Cos Inc. $BHC

Key Points

• Vanguard Group Inc. has increased its stake in Bausch Health Cos Inc. by 0.5%, holding 11,746,480 shares valued at approximately $76 million.
• Bausch Health's director, John Paulson, significantly raised his position by purchasing over 34 million shares, increasing his ownership to nearly 70.76 million shares.
• Bausch Health reported earnings of $0.90 per share in its latest quarter, missing analyst expectations, but achieved revenues of $2.57 billion, exceeding estimates.

Vanguard Group Inc. raised its holdings in Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 0.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,746,480 shares of the company's stock after purchasing an additional 61,621 shares during the quarter. Vanguard Group Inc. owned approximately 3.24% of Bausch Health Cos worth $76,152,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BHC. Maple Rock Capital Partners Inc. raised its position in shares of Bausch Health Cos by 156.7% during the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock worth $42,718,000 after acquiring an additional 3,235,100 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Bausch Health Cos by 3.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,113,107 shares of the company's stock worth $25,089,000 after purchasing an additional 90,166 shares during the period. Compass Rose Asset Management LP grew its stake in Bausch Health Cos by 366.7% in the fourth quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock valued at $16,926,000 after acquiring an additional 1,650,000 shares during the period. Private Management Group Inc. grew its stake in Bausch Health Cos by 13.8% in the first quarter. Private Management Group Inc. now owns 1,439,426 shares of the company's stock valued at $9,313,000 after acquiring an additional 174,176 shares during the period. Finally, Geode Capital Management LLC grew its stake in Bausch Health Cos by 12.5% in the fourth quarter. Geode Capital Management LLC now owns 715,570 shares of the company's stock valued at $5,767,000 after acquiring an additional 79,488 shares during the period. Institutional investors own 78.65% of the company's stock.

Bausch Health Cos Trading Down 1.4%

BHC traded down $0.11 during midday trading on Thursday, hitting $7.17. 453,115 shares of the company were exchanged, compared to its average volume of 2,667,189. The firm's 50 day moving average price is $6.68 and its 200-day moving average price is $6.05. Bausch Health Cos Inc. has a 1-year low of $4.25 and a 1-year high of $9.85. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The firm has a market capitalization of $2.65 billion, a P/E ratio of 27.54 and a beta of 0.41.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). The firm had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Bausch Health Cos Inc. will post 4.41 EPS for the current fiscal year.

Insider Buying and Selling at Bausch Health Cos

In related news, Director John Paulson bought 34,721,118 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The stock was bought at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the transaction, the director owned 70,755,869 shares of the company's stock, valued at approximately $636,802,821. The trade was a 96.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired a total of 44,316,834 shares of company stock valued at $369,628,560 over the last quarter. Corporate insiders own 8.05% of the company's stock.

Analysts Set New Price Targets

BHC has been the subject of a number of research analyst reports. Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Royal Bank Of Canada upped their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Bausch Health Cos currently has an average rating of "Hold" and a consensus price target of $9.00.

Bausch Health Cos Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.